Regeneron (REGN) Tops Q1 EPS by 20c; Boosts U.S. EYLEA Sales Outlook
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Canaccord Genuity Raises PT of Regeneron Pharmaceuticals (REGN) to $525 from $460
May 8, 2015 10:35 AM EDTCanaccord Genuity is reiterating their Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), as well as raising the price target to $525 (from $460), after REGN posted strong 1Q15 sales. REGN reported sales of $541M, beating out both Street and Canaccord estimates of $527M and $522M. REGN guides are being conservative, estimating a gradual initial Praulent uptake.
Canaccord Genuity analyst, John Newman, commented on (REGN) saying, "The growth was driven primarily... More
Regeneron (REGN) PT Lifted to $507 at Brean Capital Amid Strong Eylea Sales
May 8, 2015 8:26 AM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Regeneron Pharma (NASDAQ: REGN) to $507.00 (from $450.00) following strong Q1 US Eylea sales.
Aschoff commented, "1Q15 US Eylea sales of $541 million beat consensus of $537 million. Sales growth comprised a 10% QoQ increase in underlying physician demand, offset by a modest QoQ decrease in inventory levels. Importantly, Regeneron raised its guidance for 2015 US Eylea sales... More
Regeneron Pharma (REGN) Estimates, PT Lifted at Piper Jaffray
May 8, 2015 7:39 AM EDTPiper Jaffray analyst Edward Tenthoff raised his price target on Regeneron Pharma (NASDAQ: REGN) to $484.00 (from $415.00) following results but reiterated a Neutral rating.
Tenthoff commented, "U.S. EYLEA sales of $541 million in 1Q:15 topped our $534 million estimate and management increased 2015 sales growth... More
Regeneron Pharma (REGN) PT Lifted to $490 at Roth Capital
May 7, 2015 1:21 PM EDTRoth Capital analyst Joseph Pantginis raised his price target on Regeneron Pharma (NASDAQ: REGN) to $490.00 (from $461.00) following Q1 results while retaining a Neutral rating.
Pantginis commented, "Regeneron announced 1Q15 results posting GAAP EPS of $0.66 (non-GAAP of $2.88) compared with our estimate of $0.97. 1Q15... More